SNDX PEER ANALYSIS

Syndax Pharmaceuticals Inc — metric-by-metric comparison with peers and the industry median

SNDXSyndax Pharmaceuticals Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile

SNDXIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year

Split-adjusted

Year-to-Date (YTD)

Key Metric Comparison

P/E

Lower is better

ROE

Higher is better

Net Margin

Higher is better

Revenue Growth

Higher is better

All Metrics

Valuation
Metric	SNDX	TLX	MSB	CSL	RTALB	Ind. Median
P/E	—	—	—	29.96	4.78●	18.06
P/B	48.37	6.38	—	2.24	0.59●	3.62
EV/EBITDA	—	120.20	—	10.35●	72.98	15.13
P/S	9.27	3.24	31.30	2.66●	6.52	10.65

Financial Health
Metric	SNDX	TLX	MSB	CSL	RTALB	Ind. Median
Current Ratio	5.47●	1.43	—	2.57	1.21	5.90
Debt/Equity	829.8%	112.3%	—	67.4%	1.2%●	10.9%
NetDebt/EBITDA	0.04●	13.13	—	2.22	0.90	1.15

Profitability
Metric	SNDX	TLX	MSB	CSL	RTALB	Ind. Median
Net Margin	-112.0%	-0.9%	-115.3%	9.2%	136.3%●	-125.7%
ROE	-189.5%	-1.8%	-11.3%	7.7%	15.1%●	-47.5%
ROA	-43.7%	-0.7%	-8.6%	3.8%	13.1%●	-35.8%
EBITDA Margin	-74.8%	3.0%	-76.6%	32.8%●	9.0%	-105.8%

Growth + Dividend
Metric	SNDX	TLX	MSB	CSL	RTALB	Ind. Median
Rev. Growth	396.7%	56.3%	410.4%●	4.8%	24.0%	5.1%
NI Growth	—	—	—	-39.4%	134.0%●	12.1%
Div. Yield	—	—	0.0%	2.5%●	0.0%	0.2%
Payout	—	—	0.0%	103.1%	0.0%	0.0%

Valuation
Metric	SNDX	TYRA	INVA	URGN	ANAB	ZYME	Ind. Median
P/E	—	—	3.74	—	—	—	18.06
P/B	48.37	5.09	1.41	-15.25●	151.54	12.20	3.62
EV/EBITDA	—	—	2.51●	—	32.87	—	15.13
P/S	9.27	—	4.45●	13.48	8.31	24.56	10.65

Financial Health
Metric	SNDX	TYRA	INVA	URGN	ANAB	ZYME	Ind. Median
Current Ratio	5.47	20.49	21.13●	4.69	7.58	10.82	5.90
Debt/Equity	829.8%	1.5%	24.7%	-158.6%●	2,175.8%	10.4%	10.9%
NetDebt/EBITDA	0.04	2.89	-0.44	-0.48●	-0.16	3.69	1.15

Profitability
Metric	SNDX	TYRA	INVA	URGN	ANAB	ZYME	Ind. Median
Net Margin	-112.0%	—	118.9%●	-94.8%	-11.5%	-126.3%	-125.7%
ROE	-189.5%	-36.9%	50.7%●	—	-114.6%	-42.0%	-47.5%
ROA	-43.7%	-34.7%	32.6%●	-53.2%	-7.1%	-22.7%	-35.8%
EBITDA Margin	-74.8%	—	150.9%●	-82.4%	25.2%	-116.1%	-105.8%

Growth + Dividend
Metric	SNDX	TYRA	INVA	URGN	ANAB	ZYME	Ind. Median
Rev. Growth	396.7%●	-100.0%	13.6%	52.9%	107.7%	-13.0%	5.1%
NI Growth	—	—	—	—	—	—	12.1%
Div. Yield	—	—	—	—	—	—	0.2%
Payout	—	—	—	—	—	—	0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on SNDX

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 8, 26. This content is for informational purposes only and is not investment advice.